Studies
A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Safety and Efficacy of LB-P8 in Patients with Primary Sclerosing Cholangitis (PSC)
Internal Medicine
Liver Disease
Adult Subjects
The study is designed to assess the safety and efficacy of LB-P8 in patients with primary sclerosing cholangitis.
GigaGen GC2301 HBV
Internal Medicine
Liver Disease
Adult Subjects
Gilead CB8025-41837 PBC & Cirrhosis
Internal Medicine
Liver Disease
Adult Subjects
The goal of this clinical study is to learn more about the study drug, seladelpar, and its effects on clinical outcomes in participants with primary biliary cholangitis (PBC) and compensated cirrhosis.
The primary objective of this study is to evaluate the effect of seladelpar compared to placebo on EFS. EFS is defined as the time from start of treatment to the first occurrence of any of the following adjudicated events up to Week 156.